Ignite Creation Date:
2024-05-05 @ 5:12 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00404157
Status:
WITHDRAWN
Last Update Posted:
2017-04-12
First Post:
2006-11-22
Brief Title:
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Lupus Nephritis Previously Enrolled in Study U2970g
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Study Overview
Official Title:
A Phase III Extension Study to Evaluate the Safety of Rituximab Retreatment in Subjects With ISNRPS 2003 Class III or IV Lupus Nephritis Previously Enrolled in Study U2970g
Status:
WITHDRAWN
Status Verified Date:
2017-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase III multicenter extension study to evaluate the safety of rituximab administered on a scheduled basis approximately every 6 months All subjects who complete their Week 52 visit in Study U2970g will be eligible for this study as long as the inclusion and exclusion criteria are met
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None